This work reports the half maximal inhibitory concentrations, IC 50 , for conventional anti-cancer drug oxaliplatin (OXA) and potential new drugs Pt 2 Cl 2 Spm (Pt 2 Spm) and Pd 2 Cl 2 Spm (Pd 2 Spm) (Spm = Spermine) against osteosarcoma (OS). IC 50 values provided by the (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and Alamar Blue (AB) viability assays and cell density Sulforhodamine B (SRB) test were compared. Values obtained with MTT and AB were generally in agreement, and a tendency for lower IC 50 values was noted by SRB, for OXA and Pd 2 Spm. The relative suitability of different assays is discussed for each chelate. The IC 50 trend: cisplatin (cDDP) � Pd 2 Spm < OXA < Pt 2 Spm, confirmed cDDP as the most cytotoxic Pt II -agent against OS and revealed a promising performance for Pd 2 Spm. Metal chelates were also tested in combination with doxorubicin and methotrexate, the results showing that, in general, cocktails achieved comparable endperformances to that of combined cDDP, indicating that drug combination may circumvent low single-drug cytotoxicity.